New hope for Tough-to-Treat skin cancer: trial tests adding a third drug
NCT ID NCT04903119
First seen Nov 01, 2025 · Last updated Apr 11, 2026 · Updated 24 times
Summary
This early-stage study is testing whether adding a drug called nilotinib to standard melanoma treatments (dabrafenib/trametinib or encorafenib/binimetinib) is safe and tolerable for patients. It is for adults whose advanced, BRAF-mutated melanoma has stopped responding to or progressed on those standard drug combinations. The main goal is to find the safest and most effective dose of this new three-drug combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Luke's University Health Network
RECRUITINGEaston, Pennsylvania, 18045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.